• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Varenicline and buproprion more effective than varenicline alone for tobacco abstinence

bys25qthea
January 8, 2014
in Chronic Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. The combination of varenicline and buproprion for 12 weeks was more effective than varenicline alone at achieving sustained abstinence from tobacco. 

2. There was no statistically significant difference between varenicline and buproprion sustained release and varenicline alone in prevalence of smoking the past 7 days at 12 or 26 weeks.  At 52 weeks, there was no difference in abstinence two weeks after a target quit date or smoking in the past seven days. 

Evidence Rating Level:  1 (Excellent)     

Study Rundown: There are several non-nicotine pharmacotherapies for tobacco dependence.  Currently, there is interest in exploring combination therapy with existing tobacco dependence therapies.  This study is a randomized, blinded, placebo-controlled trial of varenicline and buproprion sustained release (SR) versus varenicline and placebo.  506 participants were randomized and treated for 12 weeks and followed for 40 weeks after cessation of therapy.  The combination therapy increased prolonged abstinence, defined as no smoking in the two weeks after the target quit date at 12 and 26 weeks.  However, the authors found no difference between 7-day point smoking prevalence at 12 weeks or 26 weeks.  At week 52, there was no significant difference between either of the outcomes.  A strength of this study is the use of carbon monoxide (CO) level to biochemically confirm reports of abstinence.  One weakness of the study is the fact that most participants were Caucasian.  Ultimately, a longer trial with a more diverse population will be needed to elucidate the role of combination therapy for tobacco dependence.

Click to read the study, published today in JAMA

Relevant Reading: Varenicline and bupropion sustained-release combination therapy for smoking cessation

RELATED REPORTS

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

In-Depth [randomized, blinded, placebo-controlled study]: This study looked at varenicline plus buproprion SR versus varenicline plus placebo for tobacco dependence.  506 individuals were treated for 12 weeks and followed for an additional 40 weeks. After 12 weeks of treatment, 53.0% of the combination therapy individuals achieved prolonged abstinence while only 43.2% of individuals achieving prolonged abstinence with monotherapy (OR 1.49, 95% CI 1.05-2.12, p=0.03 and OR 1.36 95% CI 0.95-1.93, p=0.09, respectively).  At 26 weeks of treatment, 36.6% of the participants on combination therapy achieved prolonged abstinence compared to 27.6% individuals on monotherapy (OR 1.52, 95% CI 1.04-2.22, p=0.03 and OR 1.32, 95% CI 0.91-1.91, p=0.14, respectively). At one year, 30.9% of the combination group achieved prolonged abstinence compared to 24.5% varenicline only group (OR 1.39, 95% CI 0.93-2.07, p=0.11 and OR 1.40, 95% CI 0.96-2.05, p=0.08).

By Jeffrey Cohen and Brittany Hasty

More from this author: Most physicians point to others to control healthcare costs, QRS morphology and duration associated with cardiac resynchronization outcomes, Repeat bone mineral density testing may not improve prediction of fracture outcomes, Risk-reduction counseling with HIV testing may not decrease rates of sexually transmitted infections, Autoantibodies may precede symptom onset in Sjögren’s Syndrome

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: smokingtobacco
Previous Post

Worldwide smoking prevalence decreasing as number of smokers increases

Next Post

Tight glycemic control in pediatric ICU does not reduce mortality

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 22, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 15, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Secondhand smoke exposure counseling may be insufficient amongst cardiology inpatients
Chronic Disease

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

April 7, 2022
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Tight glycemic control in pediatric ICU does not reduce mortality

Mitochondrial dysfunction identified in the pathogenesis of renal Fanconi’s syndrome

Mitochondrial dysfunction identified in the pathogenesis of renal Fanconi’s syndrome

Thalidomide may be effective in refractory pediatric Crohn’s disease

Preoperative low-dose steroids sufficient for steroid-treated IBD

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.